BackHemab Therapeutics Holdings Common Stock Overview

Hemab Therapeutics Holdings Common Stock Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$19.46M

As of Mar 31, 2026

Annual R&D Expenses (TTM)

N/A

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Hemab Therapeutics Holdings Common Stock (COAG) FAQ

Stockcircle tracks research & development for Hemab Therapeutics Holdings Common Stock (COAG), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Hemab Therapeutics Holdings Common Stock's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main COAG overview so you can move from this figure to the surrounding analysis quickly.